Introduction
============

Ketogenic diet (high-fat, adequate protein, and low carbohydrate diet) and ketone supplementation (exogenous ketone supplement and/or MCT) may evoke nutritional ketosis ([@B25]; [@B37]; [@B16]), which enhances conversion of ketone bodies such as beta-hydroxybutyrate and acetoacetate (AcAc) into acetyl-CoA to support ATP production ([@B45]). Under this condition, the cells utilize ketone bodies as an alternative fuel to enhance brain energy metabolism. The classical KD and variants have proven beneficial in treating epilepsy and other disorders by decreasing seizure activity ([@B28]; [@B19]), likely by modulation of GABAergic, glutamatergic, and adenosinergic processes ([@B45]; [@B32]; [@B38]). The exact mechanism(s) of the KD/nutritional ketosis on epilepsy are largely unknown and remain an area of intense investigation and interest within the pharmaceutical industry.

Genetically absence epileptic WAG/Rij rats spontaneously generate absence-like seizures, and manifest spike-wave asymmetric discharges (SWDs) on the EEG. A typical SWD contains a train of asymmetric spikes and slow waves starting and ending with sharp spikes (frequency: 7--11 Hz and duration 1--30 s in WAG/Rij rats) ([@B7]). It was demonstrated that the hyperexcitable neurons of cortical focus in the somatosensory cortex initiate SWDs (cortical focus theory) ([@B33]).

It has been demonstrated, that oral administration of βHB and AcAc in their free acid form is difficult to produce sustained ketosis, in contrast to ketone ester and ketone salt supplementation ([@B9]; [@B16]). It is well-known that adenosinergic system may be involved not only in the alleviating effect of KD/ketosis on epileptic seizures (mainly by means of A~1~Rs), but also in the modulation of absence epilepsy mechanisms ([@B10]; [@B32]; [@B23]; [@B18]). Thus, we addressed in the present study whether (i) sub-chronically (for 7 days) applied exogenous ketone supplements (KE; KS + MCT: KSMCT) by intragastric gavage can modulate absence epileptic activity and (ii) inhibition of A~1~Rs by its specific antagonist can evoke changes in seizure frequency in WAG/Rij rats. At first, to investigate the influence of the ketone supplements on absence epileptic activity, we administered KE (2.5 g/kg/day) and KSMCT (2.5 g/kg/day) alone by gavage. We measured not only glucose, but also βHB levels in the blood collected from tail veins to establish the ketonemia-inducing effect of ketone supplementation as ketonemia is the clinical hallmark associated with metabolic management of seizures ([@B11]). As we have no data on the putative effects of intraperitoneally (i.p.) injected specific A~1~R antagonist DPCPX on absence epileptic activity in WAG/Rij rats, we also investigated the effect of two doses (i.p. 0.2 and 0.5 mg/kg alone) on SWD number. Subsequently, to decide whether A~1~Rs can modify ketone supplements-evoked changes in SWD number, we applied a lower dose (i.p. 0.2 mg/kg) of DPCPX in combination with KSMCT (2.5 g/kg/day, gavage). We hypothesized that (i) exogenous ketone supplementation evokes ketosis, and decreases absence epileptic seizures, and (ii) A~1~R blockade modifies the influence of exogenous ketone supplementation on SWD number. Indeed, we demonstrated that exogenous ketone supplements increased blood βHB levels and decreased SWD number when given sub-chronically and inhibition of A~1~Rs abolished the exogenous ketone supplements-evoked changes in SWD number in WAG/Rij rats.

Materials and Methods {#s1}
=====================

Animals
-------

All animal treatments and surgery procedures were carried out according to the local ethical rules, which are in conformity with the guidelines of the Hungarian Act of Animal Care and Experimentation (1998, XXVIII, section 243), European Communities Council Directive 24 November 1986 (86/609/EEC) and EU Directive 2010/63/EU on the use and treatment of animals in experimental laboratories. The experimental design was approved by the Animal Care and Experimentation Committee of the Eötvös Loránd University (Savaria Campus) and National Scientific Ethical Committee on Animal Experimentation (Hungary) under license number VA/ÉBNTF02/85-8/2016, and was compliant with the Ethics Codex of institution. All efforts were made to minimize pain and suffering and to reduce the number of animals used.

Wistar Albino Glaxo/Rijswijk male rats (*n* = 33; 10 months old, 315--350 g; breeding colony of WAG/Rij rats at Eötvös Loránd University, Savaria Campus, Szombathely, Hungary) were housed in groups 3--4 and they were single housed after surgery. Standard laboratory conditions were as follows: 12:12 h light-dark cycle (light was on from 08.00 AM to 08.00 PM); free access to water and food; air-conditioned room (at 22 ± 2°C).

Electrode Implantation and EEG Recording
----------------------------------------

Electrode implantation was carried out under Isoflurane-air mixture (2.0--2.5%) anesthesia with stainless steel screw electrodes for EEG recording ([@B24]). Briefly, screw electrodes were placed into the bone above primary motor cortex and somatosensory cortex (A 0.8, L 1.8 and A 0.2, L 6.2, respectively) ([@B35]). A stainless steel plate (3 mm × 4 mm with one side insulated) and a screw electrode were implanted under the skin and over the masseter muscle as well as above the cerebellar cortex as reference electrode and ground electrode, respectively. The plate and electrodes were soldered to a 10-pin socket. Dentacrylate cement (Ivoclar, Liechtenstein) was used to fix electrodes and attach the socket to the skull. Lidocaine ointment (5%; EGIS, Hungary) was applied as post-operative pain relief. Rats were allowed to recover for 2 weeks. For the adaptation of rats to the experimental procedures animals were handled daily and were connected to an electroencephalograph for 5 days (adaptation to EEG recording) (**Figure [1](#F1){ref-type="fig"}**).

![Design of experiments on five animal groups. ^∗^, days of blood glucose and βHB level measuring; DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KE, ketone ester (1,3-butanediol -- acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT); PT day, post-treatment control experiment/day.](fnmol-10-00235-g001){#F1}

Electroencephalograms were recorded by an electro encephalograph (NIHON-KOHDEN, Japan) attached to a CED 1401 mkII (Cambridge Electronic Design, Ltd, United Kingdom) data capture and analysis device (the bandwidth of the EEG recording: 0.3--150 Hz; the sampling rate 500 Hz) ([@B22]). We recorded EEG between 2.30 PM and 5.00 PM. As handling may evoke stress-induced changes in behavior for about 30 min, which can modify SWD number ([@B7]; [@B22]), evaluation of SWD number, average time and total time of SWDs and sleep-waking stages were carried out between 30 and 150 min. These periods were split into 60 min sections and were evaluated separately ([@B24]). However, normal grooming and behavior and typical SWDs (**Figure [2](#F2){ref-type="fig"}**) were observed in all animals 30 min after the connection of rats to the electroencephalograph (e.g., after KE or KSMCT gavage). SWDs were separated from the EEG manually and checked by FFT analysis.

![Typical SWDs were observed in all animals 30 min after the connection of rats to the electroencephalograph in the control period (**A**; group 1) as well as after gavage of KE (**B**; 1,3-butanediol -- acetoacetate diester, 2.5 g/kg/day, group 1) and KSMCT (**C**; ketone salt + medium chain triglyceride, 2.5 g/kg/day, group 2).](fnmol-10-00235-g002){#F2}

Measuring of Blood Glucose and βHB Levels
-----------------------------------------

Blood glucose (mg/dl) and βHB (mmol/l) levels were measured from blood taken from the tail vein with a commercially available glucose and ketone monitoring system (Precision Xtra^TM^, Abbott Laboratories, Abbott Park, IL, United States) ([@B1]). This ketone monitoring system only measures blood levels of βHB, thus, total blood ketone levels (βHB + AcAc + acetone) would be higher than we measured.

Experimental Design
-------------------

Both KE (1,3-butanediol -- acetoacetate diester) and KS (Na^+^/K^+^ -- βHB mineral salt) were developed by [@B9]; University of South Florida/USF, United States) in collaboration with Savind, Inc. (Urbana, IL, United States). Ketone salt was mixed into a 50% solution (375 mg/g pure βHB and 125 mg/g of Na^+^/K^+^ in a 1:1 ratio). MCT oil (pharmaceutical grade; approximately 60% caprylic triglyceride and 40% capric triglyceride) was purchased from Now Foods (Bloomingdale, IL, United States). KS and MCT were also mixed in a 1:1 ratio (KSMCT) at the USF (United States). At first, we tested the tolerability and effectiveness of exogenous ketone supplementation (*ad libitum* access to normal rat chow + KE and KSMCT given by intragastric gavage once/day) for 7 days in the first phase of the study to assess ketonemia. Therefore, in the second phase of the study, KE (2.5 g/kg/day) and KSMCT (2.5 g/kg/day) were applied as ketone supplements alone by gavage followed by EEG recording.

Rats were assigned into five groups (**Figure [1](#F1){ref-type="fig"}**). To adapt the animals to gavage method (animal group 1/group 1, group 2 and group 5) we applied water intragastric gavage for 5 days before control treatments (between 1st and 5th day of the experiment). Then, to establish averaged control SWD numbers, SWD durations and sleep-waking stages, rats were (i) 'treated' by gavage of water (2.5 g/kg/day) (group 1, *n* = 7 and group 2, *n* = 7), (ii) injected i.p. by 0.5 ml saline/100 g body weight (b. w.; group 3, *n* = 6 and group 4, *n* = 6) or (iii) i.p. injected by 0.5 ml saline/100 g b. w., which injection was followed by the water gavage (2.5 g/kg/day) (30 min later; group 5, *n* = 7) on 5 consecutive days (5-day control period, pre-treatment control days; between 6th and 10th day of the experiment) (**Figure [1](#F1){ref-type="fig"}**). After control periods, animals of group 1 and group 2 were treated with KE (2.5 g/kg/day, group 1) and KSMCT (2.5 g/kg/day, group 2) alone for 7 consecutive days (between 11th and 17th day of the experiment) (**Figure [1](#F1){ref-type="fig"}**). Finally, the 7 days treatments by both KE and KSMCT were followed by a day of water gavage (2.5 g/kg/day; post-treatment control experiment/day: PT day) to investigate putative sustained effect of ketone supplementation on SWD number. In relation to group 3 and group 4, to investigate the effect of the specific A~1~R antagonist DPCPX on SWD number, 0.2 mg/kg (group 3) and 0.5 mg/kg (group 4) of DPCPX in 0.5 ml 10% DMSO/100 g b. w. were i.p. injected alone on the 11th day of the experiment (**Figure [1](#F1){ref-type="fig"}**). A previous study showed that 1--30% (v/v) DMSO solution have no effects on absence epileptic activity in WAG/Rij rats ([@B20]). To reveal the putative influence of A~1~R blockade on ketone supplements-evoked changes in SWD number, combined application of (i) i.p. saline injection (0.5 ml/100 g b. w.) with KSMCT gavage (2.5 g/kg/day, between 11th and 15th day of the experiment), (ii) i.p. 0.2 mg/kg DPCPX with KSMCT (2.5 g/kg/day) on the 6th day of KSMCT gavage (16th day of the experiment; DPCPX injection preceded the gavage by 30 min) and (iii) i.p. saline injection with KSMCT gavage (last day of the experiment; group 5) were carried out (**Figure [1](#F1){ref-type="fig"}**).

To investigate the effect of ketone supplements (KE and KSMCT) on blood glucose and βHB levels we measured them on the last (5th) control day (control), on the days of the 1st and the 7th ketone supplement gavage and on PT day (on the 10th, 11th, 17th, and 18th day of experiments, respectively; group 1 and group 2) (**Figure [1](#F1){ref-type="fig"}**). The body weight of rats were also measured before treatments by ketone supplement started (5th control day: control) and after the last (7th) ketone supplement treatments (on the 10th and 17th day of experiments, respectively; group 1 and group 2).

As changes in sleep-waking ratios may modulate SWD number in WAG/Rij rats ([@B6]; [@B7]) and as we had no prior data on putative effects of ketone supplements, DPCPX and combined application of DPCPX with KSMCT on sleep-waking stages, we investigated their effect (after 6th gavage of 2.5 g/kg KSMCT alone/group 2, i.p. 0.2 mg/kg DPCPX alone/group 3 and combined application of i.p. 0.2 mg/kg DPCPX with 2.5 g/kg KSMCT/group 5) not only on SWD number, SWD time (average time of SWDs) and discharge frequency within SWDs, but also on sleep-waking stages between 30 and 90 min. The effect of 2.5 g/kg KE (group 1) on SWD time and discharge frequency within SWDs was also investigated between 30 and 90 min. Evaluation of sleep-waking stages was performed offline by visual evaluation of the raw EEG. We distinguished wakefulness (predominantly beta/20--40 Hz and theta/6--8 Hz activity: wake; passive/active wake: without/with high slow waves of motor artifacts), SWS (sleep spindles/10--16 Hz, theta waves and some slow waves/2--4 Hz: light SWS; disappearance of sleep spindles and increasing ratio of high slow delta waves/0.5--4 Hz: deep SWS) and REM sleep (continuous theta activity without any motor artifacts) in 60 min epochs ([@B24]).

All results (SWD number, SWD time, discharge frequency within SWDs, sleep-waking stages, b. w. as well as blood level of glucose and βHB) were expressed as means ± standard error of the mean. The pre-treatment control values were the grand average calculated (i) from the results of 5 control days (5-day control period; in relation to SWD number, SWD time, discharge frequency within SWDs and sleep-waking stages) or (ii) from the values measured on the last (5th) control days (in case of b. w. and blood level of glucose and βHB). Results were evaluated by One- or Two-way Repeated Measure Analysis of Variance and significance levels were determined by Dunnett's Multiple Comparison Test and Bonferroni's *Post hoc* Tests as were described previously ([@B22]).

Results
=======

Effect of Exogenous Ketone Supplements on SWD Number, Blood βHB, Glucose Levels, and Body Weight
------------------------------------------------------------------------------------------------

Significant decrease in SWD number was demonstrated after both KE (2.5 g/kg/day, group 1) and KSMCT (2.5 g/kg/day, group 2) treatment between 3rd and 7th days of gavage from 30 to 150 min (**Figures [3A,B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**) compared to control levels. Moreover, SWD numbers were similar to the control levels on PT days (2.5 g/kg water gavage) (**Figures [3A,B](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**).

![Effect of KE (gavage, 2.5 g/kg/day, group 1) and KSMCT (gavage, 2.5 g/kg/day, group 2) on SWD number (**A,B**, respectively) as well as on βHB and glucose levels (KE: **C,E**; KSMCT: **D,F**). 1KE, 1st KE application (gavage); 2KE, 2nd KE application and so on; 1KS, 1st KSMCT application (gavage); 2KS, 2nd KSMCT application and so on (KSMCT, ketone salt/KS + medium chain triglyceride/MCT); 1PT, post-treatment control experiment (2.5 g/kg water gavage); βHB, beta-hydroxybutyrate; CON, control; KE, ketone ester (1,3-butanediol -- acetoacetate diester); SWD, spike-wave discharge. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001 level of significance.](fnmol-10-00235-g003){#F3}

###### 

Effects of KE (gavage, 2.5 g/kg/day, group 1) and KSMCT (gavage, 2.5 g/kg/day, group 2) on SWD number.

  ------------------------------------------------------------------------------------------------------------------------------------------
  Treatments                                                               The effect of treatment   SWD number (mean ± SEM)   
  ------------------------------------------------------------------------ ------------------------- ------------------------- -------------
  **2.5 g/kg/day KE (**Figure [3A](#F3){ref-type="fig"}**, group 1)**                                                          

                                                                                                                               

  **Control (CON)**                                                        30--90 min: ^∗∗∗^/        15.5 ± 0.9                17.1 ± 1.6

  1st KE treatment (1KE)                                                   8.541                     12.9 ± 2.1\               12.7 ± 1.5\
                                                                                                     -/1.602                   -/2.018

  2nd KE treatment (2KE)                                                   90--150 min: ^∗∗∗^/\      14.1 ± 1.7\               13.1 ± 2.9\
                                                                           6.010                     -/0.827                   -/1.821

  3rd KE treatment (3KE)                                                                             10.0 ± 1.5\               11.1 ± 1.2\
                                                                                                     ^∗^/3.324                 ^∗^/2.804

  4th KE treatment (4KE)                                                                             8.4 ± 0.9\                8.1 ± 0.6\
                                                                                                     ^∗∗∗^/4.271               ^∗∗^/4.115

  5th KE treatment (5KE)                                                                             6.9 ± 0.4\                6.9 ± 0.9\
                                                                                                     ^∗∗∗^/5.218               ^∗∗∗^/4.704

  6th KE treatment (6KE)                                                                             7.1 ± 0.5\                7.3 ± 0.8\
                                                                                                     ^∗∗∗^/5.046               ^∗∗∗^/4.508

  7th KE treatment (7KE)                                                                             6.9 ± 0.8\                6.4 ± 1.2\
                                                                                                     ^∗∗∗^/5.218               ^∗∗∗^/4.901

  Post-treatment control experiment (1PT)                                                            13.3 ± 1.8\               14.1 ± 1.2\
                                                                                                     -/1.343                   -/1.363

                                                                                                                               

  **2.5 g/kg/day KSMCT (**Figure [3B](#F3){ref-type="fig"}**, group 2)**                                                       

                                                                                                                               

  **Control (CON)**                                                        30--90 min: ^∗∗∗^/        17.8 ± 1.2                17.1 ± 0.7

  1st KSMCT treatment (1KS)                                                14.000                    16.4 ± 1.8\               15.1 ± 2.9\
                                                                                                     -/0.884                   -/0.855

  2nd KSMCT treatment (2KS)                                                90--150 min: ^∗∗∗^/\      13.9 ± 1.1\               13.0 ± 2.3\
                                                                           5.404                     -/2.575                   -/1.785

  3rd KSMCT treatment (3KS)                                                                          11.1 ± 0.9\               8.9 ± 1.5\
                                                                                                     ^∗∗∗^/4.361               ^∗∗^/3.582

  4th KSMCT treatment (4KS)                                                                          10.0 ± 0.5\               9.6 ± 0.5\
                                                                                                     ^∗∗∗^/5.113               ^∗^/3.273

  5th KSMCT treatment (5KS)                                                                          8.0 ± 0.6\                7.4 ± 0.9\
                                                                                                     ^∗∗∗^/6.429               ^∗∗∗^/4.202

  6th KSMCT treatment (6KS)                                                                          7.9 ± 0.5\                7.7 ± 0.5\
                                                                                                     ^∗∗∗^/6.523               ^∗∗^/4.078

  7th KSMCT treatment (7KS)                                                                          7.3 ± 0.4\                6.9 ± 0.5\
                                                                                                     ^∗∗∗^/6.899               ^∗∗∗^/4.450

  Post-treatment control experiment (1PT)                                                            15.0 ± 2.4\               14.0 ± 2.6\
                                                                                                     -/1.823                   -/1.351
  ------------------------------------------------------------------------------------------------------------------------------------------

KE, ketone ester (1,3-butanediol -- acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT; SWD, spike-wave discharge.

∗

p

\< 0.05,

∗∗

p

\< 0.01, and

∗∗∗

p

\< 0.001 level of significance.

Blood βHB and glucose levels were significantly increased and unchanged, respectively, after the 1st and 7th KE (2.5 g/kg/day, group 1) or KSMCT (2.5 g/kg/day, group 2) gavage (**Figures [3C](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**) compared to control levels. The βHB and glucose levels returned to the baseline (control) levels on the PT day (**Figures [3C](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**).

###### 

Influence of KE (gavage, 2.5 g/kg/day, group 1) and KSMCT (gavage, 2.5 g/kg/day, group 2) on blood βHB and glucose levels.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Treatments                                                                  The effect of treatment   Blood βHB and glucose levels   
  --------------------------------------------------------------------------- ------------------------- ------------------------------ -------------
  **2.5 g/kg/day KE (**Figures [3C,E](#F3){ref-type="fig"}**, group 1)**                                                               

                                                                                                                                       

  **Control (CON)**                                                           Glucose: -/2.768          0.8 ± 0.1                      98.0 ± 3.8

  1st KE treatment (1KE)                                                      \                         1.8 ± 0.1\                     86.4 ± 3.7\
                                                                              βHB: ^∗∗∗^/50.090         ^∗∗∗^/9.120                    -/2.538

  7th KE treatment (7KE)                                                                                1.6 ± 0.1\                     94.6 ± 2.7\
                                                                                                        ^∗∗∗^/7.707                    -/0.752

  Post-treatment control experiment (1PT)                                                               0.7 ± 0.1\                     97.6 ± 3.3\
                                                                                                        -/0.385                        -/0.094

                                                                                                                                       

  **2.5 g/kg/day KSMCT (**Figures [3D,F](#F3){ref-type="fig"}**, group 2)**                                                            

                                                                                                                                       

  **Control (CON)**                                                           Glucose: -/1.552          0.9 ± 0.0                      94.6 ± 3.7

  1st KSMCT treatment (1KS)                                                   \                         1.8 ± 0.2\                     87.8 ± 3.6\
                                                                              βHB: ^∗∗∗^/41.180         ^∗∗∗^/7.334                    -/1.633

  7th KSMCT treatment (7KS)                                                                             1.9 ± 0.1\                     93.3 ± 2.7\
                                                                                                        ^∗∗∗^/8.011                    -/0.299

  Post-treatment control experiment (1PT)                                                               0.9 ± 0.1\                     96.3 ± 5.2\
                                                                                                        -/0.339                        -/0.399
  --------------------------------------------------------------------------------------------------------------------------------------------------

βHB, beta-hydroxybutyrate; KE, ketone ester (1,3-butanediol -- acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT.

∗∗∗

p

\< 0.001 level of significance.

We did not find significant changes in b. w. of animals after KE (group 1) and KSMCT (group 2) application compared to control levels \[b. w. of rats (g) on the 5th control day/after the 7th KE or KSMCT treatments ± SEM; control/KE: 323.3 ± 7.9/324.2 ± 8.1, *q* = 1.005; control/KSMCT: 335.6 ± 7.4/334.7 ± 6.7, *q* = 0.633\].

Effect of DCPX Alone and in Combination with KSMCT on SWD Number
----------------------------------------------------------------

We demonstrated that a lower dose of DPCPX (i.p. 0.2 mg/kg, group 3) alone did not change the SWD number whereas the higher dose (i.p. 0.5 mg/kg, group 4) alone significantly increased the SWD number between 30 and 90 min after injection (**Figures [4A,B](#F4){ref-type="fig"}** and **Table [3](#T3){ref-type="table"}**). However, the tendency in SWD number after the i.p. injection of higher DPCPX dose (control/DPCPX ± SEM: 13.5 ± 1.3/16.2 ± 1.9, *t* = 2.406) between 90 and 150 min was not significant (**Figure [4B](#F4){ref-type="fig"}** and **Table [3](#T3){ref-type="table"}**).

![Effect of i.p. 0.2 mg/kg DPCPX (**A**, group 3), i.p. 0.5 mg/kg DPCPX (**B**, group 4) as well as KSMCT gavage (1KS -- 5KS and 7KS) and combined application of i.p. 0.2 mg/kg DPCPX with KSMCT on day of 6th KSMCT gavage (6KS+D; **C**, group 5) on SWD number. 1KS, 1st KSMCT application (gavage); 2KS, 2nd KSMCT application and so on; 6KS+D, combined application of i.p. 0.2 mg/kg DPCPX with KSMCT on day of 6th KSMCT gavage (the gavage of KSMCT was preceded by i.p. injection of DPCPX by 30 min); CON, control; DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; SWD, spike-wave discharge. ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 level of significance.](fnmol-10-00235-g004){#F4}

###### 

Changes in SWD number after i.p. injection of two doses of DPCPX (i.p. 0.2 mg/kg DPCPX: group 3; i.p. 0.5 mg/kg DPCPX: group 4).

  --------------------------------------------------------------------------------------------------------------------------------------------
  Treatments                                                                 The effect of treatment   SWD number (mean ± SEM)   
  -------------------------------------------------------------------------- ------------------------- ------------------------- -------------
  **i.p. 0.2 mg/kg DPCPX (**Figure [4A](#F4){ref-type="fig"}**, group 3)**                                                       

                                                                                                                                 

  **Control**                                                                -/1.979                   15.9 ± 0.6                17.4 ± 0.4

  DPCPX                                                                                                17.3 ± 1.6\               18.2 ± 0.9\
                                                                                                       -/1.271                   -/0.719

                                                                                                                                 

  **i.p. 0.5 mg/kg DPCPX (**Figure [4B](#F4){ref-type="fig"}**, group 4)**                                                       

                                                                                                                                 

  **Control**                                                                ^∗∗∗^/102.700             15.4 ± 1.7                13.5 ± 1.3

  DPCPX                                                                                                28.7 ± 2.3\               16.2 ± 1.9\
                                                                                                       ^∗∗∗^/11.930              -/2.406
  --------------------------------------------------------------------------------------------------------------------------------------------

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; SWD, spike-wave discharge.

∗∗∗

p

\< 0.001 level of significance.

A similar decrease in SWD number was observed after both KE and KSMCT gavage between 1st and 7th gavage days, but the change in SWD number was slightly smoother in relation to KSMCT (**Figures [3A,B](#F3){ref-type="fig"}**). Moreover, based on previous studies ([@B45]; [@B32]; [@B38]), we hypothesized that the mechanism(s) of action on epileptic activity may be similar for KE and KSMCT. Thus, we used only KSMCT (2.5 g/kg/day) for combined application with DPCPX (group 5). In addition, we selected the lower dose of DPCPX (0.2 mg/kg) for combined application to decrease its putative side effects and because we wanted to inhibit (antagonize) A~1~Rs without increasing seizure activity (**Figures [4A,B](#F4){ref-type="fig"}**). As we did not find an effect of a lower DPCPX dose on behavior and as we demonstrated only a very slight and insignificant increase or decrease in SWD number, average SWD duration and discharge frequency within SWDs after its i.p. application alone (**Figure [4A](#F4){ref-type="fig"}**), we used this non-pro-epileptic dose of DPCPX (i.p. 0.2 mg/kg) in combination with KSMCT (2.5 g/kg/day) on the 6th day of KSMCT gavage, when, without DPCPX, KSMCT alone significantly decreased the SWD number (**Figure [3B](#F3){ref-type="fig"}**). As **Figure [4C](#F4){ref-type="fig"}** shows, i.p. 0.2 mg/kg DPCPX abolished the KSMCT-evoked decrease in SWD number on the 6th day of KSMCT gavage (**Figures [3B](#F3){ref-type="fig"}, [4C](#F4){ref-type="fig"}** and **Table [4](#T4){ref-type="table"}**; group 5).

###### 

Effect of KSMCT gavage (2.5 g/kg/day; between 1st and 5th KSMCT treatment/1KS -- 5KS and on the 7th day of KSMCT application/7KS) and combined application of DPCPX (i.p. 0.2 mg/kg) with KSMCT gavage (DPCPX + 6th KSMCT treatment/6KS + D, group 5) on SWD number.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatments                                                                                      The effect of treatment   SWD number (mean ± SEM)   
  ----------------------------------------------------------------------------------------------- ------------------------- ------------------------- -------------
  **i.p. 0.2 mg/kg DPCPX + 2.5 g/kg/day KSMCT (**Figure [4C](#F4){ref-type="fig"}**, group 5)**                                                       

                                                                                                                                                      

  **Control (CON)**                                                                               30--90 min: ^∗∗∗^/        17.9 ± 0.9                16.9 ± 0.8

  1st KSMCT treatment (1KS)                                                                       20.470                    15.6 ± 1.7\               15.7 ± 1.6\
                                                                                                                            -/2.400                   -/1.195

  2nd KSMCT treatment (2KS)                                                                       90--150 min: ^∗∗∗^/\      13.1 ± 1.4\               12.9 ± 0.7\
                                                                                                  32.340                    ^∗∗^/4.829                ^∗∗∗^/4.181

  3rd KSMCT treatment (3KS)                                                                                                 10.7 ± 0.6\               9.1 ± 0.7\
                                                                                                                            ^∗∗∗^/7.257               ^∗∗∗^/8.064

  4th KSMCT treatment (4KS)                                                                                                 9.3 ± 1.1\                9.4 ± 0.7\
                                                                                                                            ^∗∗∗^/8.686               ^∗∗∗^/7.765

  5th KSMCT treatment (5KS)                                                                                                 8.4 ± 1.0\                7.7 ± 0.5\
                                                                                                                            ^∗∗∗^/9.543               ^∗∗∗^/9.557

  DPCPX + 6th KSMCT treatment (6KS+D)                                                                                       18.3 ± 0.9\               16.4 ± 0.8\
                                                                                                                            -/-0.314                  -/0.448

  7th KSMCT treatment (7KS)                                                                                                 9.1 ± 0.4\                8.4 ± 0.7\
                                                                                                                            ^∗∗∗^/8.829               ^∗∗∗^/8.810
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KSMCT, ketone salt/KS + medium chain triglyceride/MCT; SWD, spike-wave discharge.

∗∗

p

\< 0.01 and

∗∗∗

p

\< 0.001 level of significance.

Effect of KE, KSMCT, DPCPX and Combined Application of DPCPX with KSMCT on Average SWD Duration, Discharge Frequency within SWDs and on Sleep Waking Stages
-----------------------------------------------------------------------------------------------------------------------------------------------------------

We did not find changes in the average SWD duration and discharge frequency within SWDs after application of KE (2.5 g/kg/day, 6th gavage, group 1), KSMCT (2.5 g/kg/day, 6th gavage, group 2), DPCPX (i.p. 0.2 mg/kg, group 3) alone and combined application of DPCPX (i.p. 0.2 mg/kg) with KSMCT (2.5 g/kg/day, 6th gavage, group 5) between 30 and 90 min (**Table [5](#T5){ref-type="table"}**). Consequently, changes in the total time of SWDs paralleled the change in SWD number as shown in **Table [6](#T6){ref-type="table"}** (last row) (**Figures [3B](#F3){ref-type="fig"}, [4A,C](#F4){ref-type="fig"}**).

###### 

Influence of KE gavage (2.5 g/kg/day, 6th treatment, group 1), KSMCT gavage (2.5 g/kg/day, 6th treatment, group 2) and i.p. DPCPX (0.2 mg/kg, group 3) alone and combined application of i.p. DPCPX with KSMCT gavage (i.p. 0.2 mg/kg DPCPX + 6th KSMCT treatment, group 5) on average SWD duration and discharge frequency within SWDs between 30 and 90 min.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatments                                                Average SWD duration (sec; (mean ± SEM) and Bonferroni's *post hoc* test (significance/*t*-value)   Discharge frequency within SWDs (Hz; mean ± SEM) and Bonferroni's *post hoc* test (significance/*t*-value)
  --------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  **2.5 g/kg/day KE (group 1)**                                                                                                                                 

                                                                                                                                                                

  **Control**                                               6.5 ± 0.6                                                                                           7.9 ± 0.1

  6th KE treatment                                          6.3 ± 0.7\                                                                                          7.8 ± 0.1\
                                                            -/0.913                                                                                             -/0.197

                                                                                                                                                                

  **2.5 g/kg/day KSMCT (group 2)**                                                                                                                              

                                                                                                                                                                

  **Control**                                               6.6 ± 0.5                                                                                           7.8 ± 0.1

  6th KSMCT treatment                                       6.8 ± 0.7\                                                                                          7.9 ± 0.1\
                                                            -/0.652                                                                                             -/0.192

                                                                                                                                                                

  **0.2 mg/kg DPCPX (group 3)**                                                                                                                                 

                                                                                                                                                                

  **Control**                                               6.5 ± 0.8                                                                                           7.8 ± 0.1

  DPCPX                                                     6.3 ± 0.8\                                                                                          7.8 ± 0.1\
                                                            -/0.044                                                                                             -/0.199

                                                                                                                                                                

  **i.p. 0.2 mg/kg DPCPX + 2.5 g/kg/day KSMCT (group 5)**                                                                                                       

                                                                                                                                                                

  **Control**                                               6.7 ± 0.7                                                                                           7.8 ± 0.1

  DPCPX + 6th KSMCT treatment                               6.6 ± 0.7\                                                                                          7.8 ± 0.1\
                                                            -/0.522                                                                                             -/0.118
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KE, ketone ester (1,3-butanediol -- acetoacetate diester); KSMCT, ketone salt/KS + medium chain triglyceride/MCT; SWD, spike-wave discharge.

###### 

Changes in total time of sleep-waking stages and SWDs after KSMCT gavage (2.5 g/kg/day, 6th treatment, group 2) and DPCPX injection (i.p. 0.2 mg/kg, group 3) alone and combined application of i.p. DPCPX with KSMCT gavage (i.p. 0.2 mg/kg DPCPX + 6th KSMCT treatment, group 5) between 30 and 90 min.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sleep-waking stages and SWD   Total duration of sleep-waking stages and SWDs (sec; mean ± SEM) and Bonferroni's *post hoc* test (significance/*t*-value)                                                                   
  ----------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------- --------------- --------------- -------------- ----------------
  **Active wake**               702.7 ± 16.1                                                                                                                 720.8 ± 15.4\    675.8 ± 22.0    671.9 ± 19.3\   688.2 ± 15.4   697.5 ± 16.9\
                                                                                                                                                             -/1.027                          -/0.141                        -/0.440

  **Passive wake**              704.1 ± 7.3                                                                                                                  714.5 ± 10.4\    731.9 ± 15.8    741.2 ± 26.6\   704.7 ± 9.1    695.2 ± 16.8\
                                                                                                                                                             -/0.598                          -/0.346                        -/0.447

  **Light SWS**                 990.2 ± 10.9                                                                                                                 988.1 ± 18.1\    974.2 ± 17.7    973.0 ± 23.8\   981.0 ± 17.9   963.8 ± 11.6\
                                                                                                                                                             -/0.121                          -/0.042                        -/0.817

  **Deep SWS**                  976.2 ± 15.9                                                                                                                 1002.9 ± 17.2\   1002.1 ± 24.6   997.3 ± 38.4\   993.9 ± 20.3   1004.9 ± 23.2\
                                                                                                                                                             -/1.525                          -/0.178                        -/0.517

  **REM**                       108.5 ± 3.2                                                                                                                  115.3 ± 2.7\     111.2 ± 7.5     106.5 ± 8.4\    110.6 ± 4.0    112.0 ± 10.8\
                                                                                                                                                             -/0.388                          -/0.175                        -/0.067

  **SWD**                       118.3 ± 7.3                                                                                                                  58.4 ± 3.6\      104.9 ± 3.9     110.0 ± 9.6\    121.6 ± 5.9    126.6 ± 8.1\
                                                                                                                                                             ^∗∗^/3.566                       -/0.190                        -/0.239
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; KSMCT, ketone salt/KS + medium chain triglyceride/MCT; REM, rapid eye movement; SWD, spike-wave discharge; SWS, slow wave sleep;

∗∗

p

\< 0.01 level of significance.

The total time of sleep-waking stages was not changed after application of KSMCT (6th gavage, group 2), DPCPX (i.p. 0.2 mg/kg, group 3) alone and combined application of DPCPX with KSMCT (6th gavage, group 5) between 30 and 90 min (**Table [6](#T6){ref-type="table"}**).

Discussion
==========

The current study is the first to demonstrate that the sub-chronic application of exogenous ketone supplements (both KE and KSMCT) by intragastric gavage decreased absence epileptic activity, and was abolished by pharmacologic inhibition of A~1~Rs in WAG/Rij rats.

It has been demonstrated that different types of ketogenic diets represent alternative treatment methods (metabolic-based therapies) for a broad range of seizure disorders, in which decreased epileptic activity may be related to elevations in serum ketone bodies, reduced glucose levels, suppression of insulin signaling as well as different neurotransmitter systems, such as GABAergic and adenosinergic system in different types of epilepsies ([@B39]; [@B43]; [@B40]; [@B38]). Although the relationship between KD-evoked ketosis and seizure arrest is still unclear, it is widely accepted that high level ketosis has an important role in antiseizure/anticonvulsant effects of KD: βHB may alter metabolic pathways to increase both GABA and adenosine, which products have anticonvulsant and seizure suppressive effects ([@B12]; [@B2]; [@B34]; [@B43]; [@B40]). Nevertheless, many patients have difficulty with compliance to the KD because of gastrointestinal symptoms including vomiting, diarrhea and abdominal pain ([@B39]; [@B44]). Therefore, testing new, non-pharmacological therapeutic strategies, such as application of exogenous ketone supplements instead of strict KD ([@B27]), which supplements may sustain therapeutic levels of ketosis are needed for some individuals. Exogenous ketone supplementation may generate corresponding beneficial therapeutic effect on epileptic seizures similar to the KD because (i) exogenous ketone supplementation-evoked influences may be similar to effects of KD (such as increased adenosine level), whose actions may mediate the effects of ketone supplementation on different types of epilepsies, (ii) among others, ketone bodies (e.g., βHB) may be responsible for the mediating effects of KD/ketosis as well as ketone supplementation on epileptic seizures due to altering Krebs cycle intermediates and GABAergic activity, and (iii) ketone supplementation (both KE and KSMCT) increase blood βHB levels and evoke nutritional ketosis at levels known to preserve brain homeostasis (**Figures [3C,D](#F3){ref-type="fig"}**) ([@B25]; [@B45]; [@B32]; [@B37]; [@B1]; [@B16]; [@B38]). Moreover, tolerability of oral/intragastric exogenous ketone supplementation in inducing nutritional ketosis is consistent with previous studies ([@B16]), and provides a rationale for circumventing the dietary restriction of the KD or to enhance ketogenesis in less restrictive modified versions.

It was previously demonstrated that KD/ketosis may be effective against absence epileptic activity ([@B39]; [@B13]; [@B41]; [@B5]; [@B18]; [@B27]). Our results suggest that not only KD, but also sub-chronically applied ketone supplements KE and KSMCT, administered by gavage, can increase βHB levels and decrease SWD number in freely moving WAG/Rij rats (**Figures [3A](#F3){ref-type="fig"}--[D](#F3){ref-type="fig"}**). Moreover, SWD number and βHB level returned to the control level after both KE and KSMCT treatments (on the PT days). Thus, our results suggest that after ketone supplementation the absence epileptic activity can decrease in correlation with the increase in βHB level, which strengthens the support for nutritional ketosis as a means to suppress absence epileptic seizures ([@B39]; [@B13]; [@B41]; [@B5]; [@B18]; [@B27]).

Moreover, it has been demonstrated that KD and ketone bodies (direct and/or indirect manner) among others may (i) increase adenosine signaling by both decreased expression/activity of adenosine kinase (which enzyme may metabolize adenosine) and enhanced βHB metabolism and, as a consequence, by A~1~Rs and (ii) enhance the inhibitory GABAergic effects in the brain by GABA~A~ receptors ([@B45]; [@B32], [@B31]; [@B40]; [@B38]), which systems (GABAergic and adenosinergic) may have a role in the regulation of absence epileptic activity in WAG/Rij rats ([@B36]; [@B10]; [@B22]). It was demonstrated previously that activation of A~2A~Rs and GABA~A~ receptors may evoke increases in SWD number in WAG/Rij rats ([@B10]; [@B22]; [@B26]), which results suggest that the modificatory effects of GABA~A~ receptors and A~2A~Rs in ketone supplementation-evoked decrease in absence epileptic activity can be excluded. Density of A~1~Rs is uneven in the central nervous system, expression/activity of A~1~Rs is decreased in the somatosensory cortex (focus) and thalamus in presymptomatic WAG/Rij rats, A~1~Rs has a role in the modulation of different types of epilepsies, and KDs may exert their effect on epileptic activity by means of A~1~Rs ([@B10]; [@B21], [@B23]; [@B32]). Furthermore, (i) SWDs triggered by excessive hyperexcitability in the cortical focus of absence epilepsy genesis ([@B33]; [@B7]), (ii) brain areas, implicated in absence epilepsy genesis, such as somatosensory cortex, contain A~1~Rs ([@B8]; [@B21]) and (iii) not only KD, but also ketone supplementation may modulate adenosinergic system by increased adenosine levels ([@B32]; [@B40]; [@B38]). It has been demonstrated previously that inhibition of A~1~Rs by DPCX induces seizure-like bursting activity *in vitro* ([@B42]) and A~1~R knockout mouse exhibits electrographic seizures *in vivo* ([@B32]). Moreover, in accordance with cortical focus theory of absence epilepsy ([@B33]; [@B7]), activation of inhibitory A~1~Rs, which may decrease the excessive hyperexcitability in the somatosensory cortex (cortical focus) directly and indirectly by synaptic inhibition with reducing Ca^2+^ influx through voltage-dependent Ca^2+^ channels, and activation of both ATP-sensitive potassium (K~ATP~) channels and G protein-gated inwardly rectifying potassium channels hyperpolarizing neuronal membranes ([@B23]; [@B29]; [@B38]), may decrease absence epileptic activity. In addition, ketosis/ketone bodies may indirectly activate K~ATP~ channels ([@B30]). All of these inhibitory effects may be implicated in the modulatory effect of A~1~Rs on KE and KSMCT treatment-evoked changes in epileptic seizures (**Figure [4C](#F4){ref-type="fig"}**), and/or strengthened the aggravating effect of higher dose of DPCPX on SWD number (**Figure [4B](#F4){ref-type="fig"}**) in WAG/Rij rats.

As to the antiepileptic effect of ketone supplementation, additional mechanisms of action similar to KD cannot be excluded ([@B38]). For example, depending on the diet formulation, KD/ketosis may result in (i) increased level of two potentially anti-convulsant fatty acids decanoic acid and octanoic acid, (ii) modified synaptic vesicle recycling by means of βHB ([@B4]; [@B14]), (iii) appearance of adenosine-associated epigenetic mechanism(s) ([@B29]), (iv) increased threshold for calcium-induced mitochondrial permeability transition ([@B17]), and (v) decrease in extracellular glutamate release ([@B15]), which effects may also alleviate epileptic seizures. For example, it has been demonstrated that MCT may evoke anti-seizure effect by decanoic acid through AMPA receptor inhibition *in vitro* ([@B3]). Consequently, several mechanisms of action might be involved in KD- and ketone supplementation-evoked antiepileptic/antiseizure effects. However, our data are not sufficient to interpret all of the putative mechanisms, by which (i) exogenous ketone supplementation exerts its antiepileptic effects and (ii) A~1~Rs modulate effects of ketone supplements on seizure activity.

Conclusion
==========

The administration of exogenous ketone supplements without dietary restrictions (standard rodent diet) may be an effective alternative way to the KD not only to reach and maintain nutritional ketosis, but also to reduce epileptic activity, and which can be reversed by inhibition of A~1~Rs. Our results on WAG/Rij rats and modulation of ketone supplementation-evoked effects on absence epileptic activity provided an opportunity to investigate some new aspects of the pathophysiology of absence epilepsy, several signaling pathways, which are still poorly understood, influence of ketone supplementation on epileptic activity and the correlation between antiepileptic activity of ketone supplementation and their potential to induce ketosis. Our results may contribute to the development of effective antiepileptic strategies such as ketone supplementation not only against absence epilepsy (e.g., childhood absence epilepsy), but also for other therapy-resistant types of epilepsies, which may afford long-lasting seizure protection. Therefore, further studies are needed to reveal the exact molecular and neuropharmacological effects of exogenous ketone supplementation-induced decrease in absence epileptic activity and to disclose the putative link(s) between exogenous ketone supplements-evoked and adenosine-generated effects on seizure activity.
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A~1~R

:   adenosine A~1~ receptor

A~2A~R

:   adenosine A~2A~ receptor

AcAc

:   acetoacetate

ATP

:   adenosine triphosphate

βHB

:   beta-hydroxybutyrate

DMSO

:   dimethyl sulfoxide

DPCPX

:   1,3-dipropyl-8-cyclopentylxanthine

EEG

:   electroencephalogram

FFT

:   fast Fourier transform

GABA

:   gamma-aminobutyric acid

i.p.

:   intraperitoneal

K~ATP~ channels

:   ATP-sensitive potassium channels

KD

:   ketogenic diet

KS

:   ketone salt

KSMCT

:   ketone salt/KS + medium chain triglyceride/MCT

MCT

:   medium chain triglyceride

PT day

:   post-treatment control experiment/day

REM sleep

:   rapid eye movement sleep

S.E.M.

:   standard error of the mean

SWD

:   spike-wave discharge

SWS

:   slow wave sleep

WAG/Rij

:   Wistar Albino Glaxo/Rijswijk
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